Oral Immunotherapy in 2026: Food Allergy Care Is Finally Getting Active

For decades, food allergy management was 'avoid the food and carry an EpiPen'. In 2026, oral immunotherapy (OIT) for peanut and other major food allergens is a real option that materially reduces severe reaction risk — though it isn't a cure.

What OIT actually does

• Daily small graduated doses of the allergen — not a cure, but a clinically meaningful raise in reaction threshold.
• Approved peanut OIT (Palforzia) in many markets, with non-Palforzia/'real food' OIT also widely practised in specialist clinics.
• Threshold change matters — many treated children move from reacting to one peanut to tolerating accidental exposure (a few peanuts).

Who benefits the most

• School-age children with severe peanut allergy — the most-studied population, with strong threshold-raising data.
• Children with low quality of life from constant avoidance — psychological benefit is substantial in motivated families.
• Adolescents and young adults — possible but lower tolerability and adherence challenges.

Trade-offs and ongoing care

• GI side effects and ongoing reaction risk during build-up — done only in supervised allergist programmes.
• Daily maintenance dosing — stopping the daily dose typically returns reactivity over weeks.
• Epinephrine still required — OIT raises threshold, doesn't eliminate anaphylaxis risk.

What this means for patients and practising clinicians

If your child has a severe peanut or other food allergy, ask an allergist about OIT — even if the answer is 'not the right time yet'. The 2026 evidence has reset the goal of food allergy care from pure avoidance to active threshold-raising.

*This article was drafted by the DocSite AI Team and reviewed for clinical accuracy. It is general medical information, not personal medical advice. For decisions about your own care, please consult a qualified specialist on DocSite.*